Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurosurgery, Berlin, Germany.
Vascular Biology and Signalling Group, ProCURE, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Catalonia, Barcelona, Spain.
Transl Stroke Res. 2022 Feb;13(1):25-45. doi: 10.1007/s12975-021-00940-2. Epub 2021 Sep 16.
Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a "puff of smoke" (Japanese: Moyamoya) on cerebral angiography. These pathological alterations of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to limit the stenotic lesions or the development of a collateral network is available, the only treatment established so far is surgical revascularization. The pathophysiology still remains unknown. Due to the early age of onset, familial cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be replicated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells, cytokines and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a ubiquitously expressed 591 kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed as a susceptibility gene in several studies with a gene dosage-dependent clinical phenotype, allowing preventive screening and possibly the development of new therapeutic approaches. This review focuses on the genetic basis of primary MMD only.
烟雾病(MMD)是一种罕见的脑血管疾病,其特征为颅内颈内动脉(ICA)及其主要分支进行性自发性双侧闭塞,脑血管造影显示吻合侧支形成“烟雾状”(日语:Moyamoya)。这些血管的病理改变称为Moyamoya 病或血管病,并进一步分为原发性和继发性 MMD。临床表现取决于年龄和人群,尤其是出血和缺血性梗死可导致严重的神经功能障碍甚至死亡。尽管 MRA 或 CTA 可提示诊断可疑性,但脑血管造影对于诊断确认是必需的。由于尚无限制狭窄病变或建立侧支网络的治疗方法,因此迄今为止唯一的治疗方法是手术血运重建。其病理生理学仍然未知。由于发病年龄较早、家族性病例以及不同种族之间的发病率不同,因此早期就将重点放在了遗传方面。已经报道了几个遗传风险位点和个别风险基因,但其中很少能在独立系列中得到复制。连锁研究显示与 17q25 位点连锁。已经进行了多项关于 SNP 与 MMD 关联的研究,主要集中在内皮细胞、平滑肌细胞、细胞因子和生长因子上。RNF213 基因的一个变体被证明与 MMD 强烈相关,在东亚人群中具有创始效应。虽然尚不清楚 RNF213 基因(编码一种广泛表达的 591kDa 胞质蛋白)的突变如何导致 MMD 的临床特征,但 RNF213 已在几项研究中被确认为易感性基因,具有基因剂量依赖性的临床表型,从而允许进行预防性筛查并可能开发新的治疗方法。本综述仅关注原发性 MMD 的遗传基础。